KEYNOTE-028: Pembrolizumab in PD-L1+ Advanced Cervical Cancer

June 3-7, 2016; Chicago, Illinois
Phase Ib trial of pembrolizumab in PD-L1–positive advanced cervical cancer showed promising 6-month OS of 67% and safety profile similar to that seen in other tumor types.
Format: Microsoft PowerPoint (.ppt)
File Size: 748 KB
Released: June 9, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Expert faculty share patient case examples from clinical practice that highlight the importance of biomarker testing for NSCLC, from Clinical Care Options (CCO)

Charles W. Flexner, MD Released: September 23, 2022

CheckMate 915: association of ctDNA and other translational factors at baseline with RFS in patients with stage IIIB-D/IV melanoma receiving adjuvant immunotherapy, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 23, 2022

Phase II SWOG S1801 study: neoadjuvant vs adjuvant treatment with pembrolizumab in patients with resectable stage III-IV melanoma, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 23, 2022

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings